The Multi-targeted Tyrosine Kinase Inhibitor Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2018
Price : $35 *
At a glance
- Drugs Dovitinib (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 18 Apr 2016 Planned End Date changed from 1 Jun 2016 to 1 Nov 2016.
- 18 Apr 2016 Status changed from recruiting to active, no longer recruiting.
- 06 Nov 2013 New trial record